4,5,6,7-Tetrahydro-1,3-Benzothiazole-2,6-Diamine Bulk Price 2026
- Market analysis indicates stable pricing for 2026 driven by optimized synthesis route efficiencies.
- Pharmaceutical grade requires industrial purity exceeding 98.0% with verified thermal stability.
- Secure bulk procurement depends on comprehensive documentation including COA and proper cold-chain logistics.
The pharmaceutical intermediate market is evolving rapidly as we approach 2026, with specific focus on key building blocks for neurological therapeutics. Among these, 4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine stands out as a critical precursor in the manufacturing of Pramipexole and related antiparkinsonian agents. Procurement managers and process chemists must understand the technical and commercial factors influencing the bulk price of this compound to ensure supply chain resilience and cost-effectiveness.
As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. recognizes that accurate forecasting requires a deep understanding of chemical properties, production scalability, and regulatory compliance. This analysis provides a technical overview of the material specifications and market dynamics expected to define the landscape in 2026.
Technical Specifications and Quality Standards
For industrial applications, particularly in the synthesis of active pharmaceutical ingredients (APIs), consistency in physical and chemical properties is paramount. The material is typically characterized as a crystalline powder with a distinct melting point that confirms structural integrity. Based on current high-performance liquid chromatography (HPLC) and gas chromatography (GC) standards, the following specifications represent the benchmark for pharmaceutical-grade inventory:
| Property | Specification |
|---|---|
| Chemical Name | 4,5,6,7-Tetrahydro-1,3-benzothiazole-2,6-diamine |
| CAS Number | 106006-83-1 |
| Molecular Formula | C7H11N3S |
| Formula Weight | 169.25 g/mol |
| Melting Point | 229°C |
| Purity (GC/HPLC) | ≥98.0% |
| Appearance | White to Yellow Crystalline Powder |
| Storage Conditions | Refrigerated (+5°C) |
Maintaining these specifications requires strict control over the manufacturing process. Deviations in melting point or coloration often indicate the presence of unreacted starting materials or oxidative byproducts, which can comp downstream purification steps. Therefore, suppliers must provide a Certificate of Analysis (COA) with every batch to verify compliance with these rigorous standards.
Synthesis Routes and Production Scalability
The economic viability of this intermediate is heavily dependent on the efficiency of the synthesis route employed. Traditional methods involve the cyclization of appropriate thiourea derivatives with cyclic ketones under controlled acidic or thermal conditions. Modern process chemistry focuses on maximizing yield while minimizing solvent waste and hazardous byproducts.
Optimized routes aim to achieve high conversion rates without compromising the industrial purity required for pharmaceutical use. Scale-up challenges often involve managing exothermic reactions and ensuring consistent crystallization during the isolation phase. Manufacturers who have invested in continuous flow chemistry or advanced crystallization technologies are better positioned to offer competitive pricing in 2026 due to reduced operational costs and higher throughput.
When evaluating potential partners for large-scale requirements, it is essential to assess their capability to handle stereospecific variations. For instance, the (S)-enantiomer is often the desired configuration for specific API formulations. Ensuring enantiomeric excess requires chiral resolution steps that can impact the final bulk price. Buyers should request detailed impurity profiles, specifically looking for related compounds such as Pramipexole Related Compound A, to ensure the material fits their specific synthetic pathway.
Market Pricing Trends and Procurement Strategy
Looking toward 2026, the pricing structure for 2,6-diamino-4,5,6,7-tetrahydro-benzthiazole derivatives is expected to stabilize as production capacities expand in key chemical manufacturing regions. However, fluctuations in raw material costs, particularly sulfur and amine sources, along with energy prices, remain variables that procurement teams must monitor.
Strategic sourcing involves more than just comparing unit costs. It requires a holistic view of total cost of ownership, which includes shipping, storage, and quality assurance. Refrigerated storage is mandatory for this compound to prevent degradation, adding logistical complexity to international shipments. Partners who offer robust cold-chain solutions and clear import documentation provide significant value beyond the initial invoice price.
For organizations seeking reliable supply chains, NINGBO INNO PHARMCHEM CO.,LTD. delivers consistent quality and technical support tailored to large-volume needs. Our commitment to transparency ensures that clients receive full documentation, including Certificates of Origin (COO) and Safety Data Sheets (SDS), facilitating smooth customs clearance and regulatory compliance.
Sourcing High-Purity Material at Scale
Securing a reliable supply of this critical intermediate requires vetting suppliers based on their technical capabilities and quality control infrastructure. When sourcing high-purity 4,5,6,7-Tetrahydro-1,3-benzothiazole-2,6-diamine, buyers should prioritize manufacturers who can demonstrate batch-to-batch consistency and provide immediate access to historical quality data.
Key considerations for procurement include:
- Volume Flexibility: Ability to scale from kilogram to tonne quantities without lead time delays.
- Quality Assurance: Availability of batch-specific COAs and retention samples for dispute resolution.
- Regulatory Support: Assistance with DMF filings or REACH compliance documentation where applicable.
- Logistical Integrity: Packaging that ensures stability during transit, adhering to the recommended +5°C storage requirement.
In conclusion, the market for 4,5,6,7-tetrahydro-2,6-benzothiazolediamine is poised for steady growth driven by demand in the neurological therapeutic sector. By focusing on technical specifications, optimized synthesis, and strategic partnerships, pharmaceutical companies can secure favorable pricing and supply security for 2026 and beyond. Prioritizing quality and documentation remains the most effective strategy for mitigating risk in the procurement of high-value pharmaceutical intermediates.